Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models.

Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models.

Osteosarcoma is the most common primary malignant bone tumour characterized by osteoid production and/or osteolytic lesions of bone. A lack of response to chemotherapeutic treatments shows the importance of exploring new therapeutic methods. Imatinib mesylate (Gleevec, Novartis Pharma), a tyrosine k...

Full description

Saved in:
Bibliographic Details
Main Authors: Bérengère Gobin, Gatien Moriceau, Benjamin Ory, Céline Charrier, Régis Brion, Frederic Blanchard, Françoise Redini, Dominique Heymann
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0090795&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items